TrialTargeted oncology2022

Methods for Estimating Long-Term Outcomes for Trastuzumab Deruxtecan in HER2-Positive Unresectable or Metastatic Breast Cancer After Two or More Anti-HER2 Therapies.

Kyle Dunton et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.